GlassScriptPhysician profile
Vamsi Rokkam
NPI 1174738389
$5,098.90
in general payments reported to CMS, 2019-2025
28 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $103 · 2021: $459 · 2022: $714 · 2023: $882 · 2024: $1,397 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,463 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.44 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $885.45 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $563.66 | 2021-2025 | |
| Amgen INC. | $355.27 | 2023-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $308.10 | 2021-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $291.05 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $284.61 | 2021-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $258.97 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $234.80 | 2021-2025 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $234.09 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $227.58 | 2024-2025 | |
| Akebia Therapeutics INC | $221.23 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $187.76 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $164.35 | 2023-2025 | Filspari |
| Abiomed | $144.41 | 2025 | |
| Opko Pharmaceuticals, LLC | $107.59 | 2019-2024 | Rayaldee |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.80 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $86.97 | 2022-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $80.76 | 2023-2024 | Gattex |
| Lilly USA, LLC | $61.42 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $58.87 | 2023-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.45 | 2024-2025 | Jynarque |
| Cormedix INC. | $43.66 | 2025 | Defencath |
| Cumberland Pharmaceuticals, INC. | $40.23 | 2019-2020 | |
| Novo Nordisk INC | $39.78 | 2023-2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $22.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.12 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.02 | 2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $16.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vamsi Rokkam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.